Murat Ozturk

Murat Ozturk

Auto-generated profile, based on publicly available information

Murat Ozturk

Department of Dermatology, Van Training and Research Hospital, Van, Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2019 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
SÖSevda Önder
Sevda Önder
MOMurat Ozturk
Murat Ozturk
Purpose: The aim of this study was to evaluate the effect of omalizumab on immunoinflammatory cells in patients with chronic spontaneous urticaria (CSU). Material and methods: The study was designed retrospectively. Seventy-four patients diagnosed with CSU and taking omalizumab between 2016-2019 were included in this study. Hematological parameters of the patients before treatment and after 12 weeks of treatment were recorded. Lymphocyte/monocyte ratio (LMR), neutrophil/monocyte ratio (NMR), neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) were examined and the effects of omalizumab treatment on inflammatory parameters were evaluated. Angioedema status of patients, total IgE levels and the relationship between these variables were investigated. The results were evaluated statistically. Results: The neutrophil count, the neutrophil/lymphocyte ratio and neutrophil/monocyte ratio showed a statistically significant reduction after 12 weeks of omalizumab treatment. There was no significant change in other data. Conclusion: In our study, omalizumab treatment significantly reduced neutrophil/lymphocyte ratio and neutrophil/monocyte ratio. Further studies are needed to assess the correlation between treatment response and these parameters to determine the likelihood of a decrease in these values by the antiinflammatory effect of omalizumab.

7 November 2019 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
MOMurat Ozturk
Murat Ozturk
IAIsa An
Isa An

9 March 2020 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
SÖSevda Önder
Sevda Önder
MOMurat Ozturk
Murat Ozturk
Aim: There are reports that isotretinoin causes some important diseases such as teratogenicity, inflammatory bowel disease and sacroiliitis by triggering inflammation. (Monocyte/HDL (high density lipoprotein) ratio) MHR is closely related to inflammation and is thought to be an indicator of atherosclerotic development. We aimed to investigate how isotretinoin (ISO) affects the immunoinflammatory response in acne patients. Materials and Methods: In this study, 116 nodulocystic acne patients who received ISO treatment for at least three months were evaluated retrospectively. ISO treatment was given to patients at a dose of 0.5-1 mg/kg. Pre-treatment and post-treatment white blood cell (WBC), neutrophil, lymphocyte, monocyte, platelet, mean platelet volume (MPV), platelet, plateletcrit, platelet distribution width (PDW), neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), total cholesterol, LDL cholesterol, triglyceride, HDL cholesterol and MHR were evaluated. Results: MPV and MHR values were significantly increased after 3 month treatment (p 0.05). There was a significant decrease in neutrophil count (p 0.05). Total cholesterol, LDL cholesterol and triglyceride levels were significantly increased after three months of treatment (p <0.05). HDL cholesterol levels decreased significantly after three months of treatment (p <0.05). Conclusion: We concluded that ISO treatment may trigger inflammation due to the increase in MPV and MHR value. MHR can show inflammation after ISO treatment.

26 October 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
IAIsa An
Isa An
MAMustafa Aksoy
Mustafa Aksoy
MOMurat Ozturk
Murat Ozturk
EAErhan Ayhan
Erhan Ayhan
TETuğba Erat
Tuğba Erat
MGMuhammet Emin Guldur
Muhammet Emin Guldur

25 October 2020 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
RARojda Aktar
Rojda Aktar
SBSerap Gunes Bilgili
Serap Gunes Bilgili
IYIbrahim Halil Yavuz
Ibrahim Halil Yavuz
GYGoknur Ozaydin Yavuz
Goknur Ozaydin Yavuz
SASiraç Aktar
Siraç Aktar
AKAyşe Serap Karadağ
Ayşe Serap Karadağ
Background Although the effect of isotretinoin use on hormonal changes in acne pathogenesis is not fully known, there are limited studies on its effects on the development of hirsutism. In this study, it was aimed to evaluate the effect of isotretinoin use on hirsutism and hormonal parameters in patients with acne vulgaris. Methods In this study, 30 female acne patients and 30 healthy females were evaluated prospectively. Menstrual irregularity, LH, FSH, Prolactin, Progesterone, 17‐OH Progesterone, Estradiol, Total testosterone, DHEA‐S, Insulin, Glucose, TSH levels, Ferriman‐Gallwey (FG) score and ultrasonography (USG) findings of control group and patient group were recorded. Results Pre‐treatment progesterone (p = 0.007) and estradiol (p = 0.001) levels of the patients were statistically lower than the control group. In the patient group, menstrual irregularity (p <001) and FG hirsutism score at the 3rd month of treatment were significantly higher than before treatment. In 10% of the patients, there were abnormal findings on pelvic USG in the third month of treatment. Conclusion In our study, it could not be revealed that isotretinoin has a significant effect on pituitary, adrenal hormones and insulin resistance. We found that three months of isotretinoin treatment caused an increase in menstrual irregularity and FG hirsutism score.

24 February 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
IAİsa An
İsa An
MAMustafa Aksoy
Mustafa Aksoy
EAErhan Ayhan
Erhan Ayhan
MOMurat Ozturk
Murat Ozturk